Literature DB >> 16971258

Drug hepatotoxicity.

Rahul A Nathwani1, Neil Kaplowitz.   

Abstract

Drug-induced liver injury is a common but underdiagnosed cause of liver disease with an incidence that is rapidly increasing. The authors address some of the more controversial aspects in relation to drug-induced liver injury: recommendations on the use of anti-tuberculosis therapy in the presence of underlying cirrhosis, the role of periodic liver test monitoring and steroid therapy in relation to drug-induced liver injury, the presence of class effects associated with certain drugs, and the potential use of ursodeoxycholic acid in prolonged cholestasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971258     DOI: 10.1016/j.cld.2006.05.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  12 in total

1.  After damage of large bile ducts by gamma-aminobutyric acid, small ducts replenish the biliary tree by amplification of calcium-dependent signaling and de novo acquisition of large cholangiocyte phenotypes.

Authors:  Romina Mancinelli; Antonio Franchitto; Eugenio Gaudio; Paolo Onori; Shannon Glaser; Heather Francis; Julie Venter; Sharon Demorrow; Guido Carpino; Shelley Kopriva; Mellanie White; Giammarco Fava; Domenico Alvaro; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2010-02-25       Impact factor: 4.307

Review 2.  Drug-induced liver injury.

Authors:  Gebran Abboud; Neil Kaplowitz
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

4.  GABA induces the differentiation of small into large cholangiocytes by activation of Ca(2+) /CaMK I-dependent adenylyl cyclase 8.

Authors:  Romina Mancinelli; Antonio Franchitto; Shannon Glaser; Fanyin Meng; Paolo Onori; Sharon Demorrow; Heather Francis; Julie Venter; Guido Carpino; Kimberley Baker; Yuyan Han; Yoshiyuki Ueno; Eugenio Gaudio; Gianfranco Alpini
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

Review 5.  Granulomatous liver disease.

Authors:  Sidharth S Bhardwaj; Romil Saxena; Paul Y Kwo
Journal:  Curr Gastroenterol Rep       Date:  2009-02

Review 6.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Prescribing medications in patients with decompensated liver cirrhosis.

Authors:  Deepak N Amarapurkar
Journal:  Int J Hepatol       Date:  2011-08-22

8.  Meta-Analysis-Based Preliminary Exploration of the Connection between ATDILI and Schizophrenia by GSTM1/T1 Gene Polymorphisms.

Authors:  Lei Cai; Mei-Hong Cai; Mei-Yan Wang; Yi-Feng Xu; Wen-Zhong Chen; Shen-Ying Qin; Chun-Ling Wan; Lin He
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

9.  A new method for identifying causal genes of schizophrenia and anti-tuberculosis drug-induced hepatotoxicity.

Authors:  Tao Huang; Cheng-Lin Liu; Lin-Lin Li; Mei-Hong Cai; Wen-Zhong Chen; Yi-Feng Xu; Paul F O'Reilly; Lei Cai; Lin He
Journal:  Sci Rep       Date:  2016-09-01       Impact factor: 4.379

Review 10.  Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis.

Authors:  Andrea Iorga; Lily Dara; Neil Kaplowitz
Journal:  Int J Mol Sci       Date:  2017-05-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.